KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.

Audrey E Kam, Fengmin Zhao, Neal J Meropol, Bruce J Giantonio, Robert B Diasio, Patrick J Flynn, Paul Catalano, Lee Hartner, Kendrith M Rowland, Wei Song, Mary F Mulcahy, Frank A Sinicrope, Robert P Whitehead, Robert J Mayer, Nicholas Petrelli, Peter J O'Dwyer, Stanley R Hamilton, David Cella, Al B Benson

Oncologist 31(1) oyaf416

PMID41397917
PMCIDPMC12795601
DOI10.1093/oncolo/oyaf416
发表日期2025-12-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Adjuvant 5-FU monotherapy was previously the standard treatment for stage II/III rectal cancer. This study compared adjuvant FOLFIRI, FOLFOX, and 5-FU/LV. METHODS: Eligible patients had T3-T4 N0 or Tany N1-3 rectal adenocarcinoma ≤12 cm from the anal verge and received pre-operative or postoperative 5-FU chemoradiotherapy (CRT). Patients were randomized to adjuvant FOLFIRI (8 cycles), FOLFOX (8 cycles), or 5-FU/LV weekly (6/8 weeks; 3 cycles). The trial planned to enroll 3,150 patients but was closed early following activation of an alternative adjuvant rectal cancer study including bevacizumab (E5204). The primary endpoint was overall survival (OS); secondary endpoints included disease-free survival (DFS), sphincter preservation, tolerability, and quality of life (QOL). RESULTS: The trial enrolled 225 patients (179 randomized) before early closure. Grade 3/4 toxicity occurred in 59%, with neutropenia, leukopenia, and diarrhea being the most common. At a median follow-up of 9.7 years, no significant OS or DFS differences were observed. The rate of sphincter preservation was numerically higher with FOLFIRI and FOLFOX versus 5-FU/LV, but the difference was not statistically significant. CONCLUSION: FOLFOX and FOLFIRI can be safely administered after CRT in rectal cancer patients safely with expected toxicities. Due to early trial closure and small sample size, the survival analysis was underpowered to detect a significant difference between regimens. CLINICALTRIALS.GOV IDENTIFIER: NCT00068692.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3. OS by treatment regimen in ITT patients.

Figure_3

OS

Figure 3 · Panel Figure_3

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel Figure_3 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 4

Figure 4. DFS by treatment regimen in ITT patients.

Figure_4

DFS

Figure 4 · Panel Figure_4

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel Figure_4 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Study schema.
非 KM Figure
Figure 2Figure 2. CONSORT diagram.
非 KM Figure